WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK plus ) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND-3

被引：0
|
作者：
Mehra, Ranee [1 ]
Felip, Enriqueta [2 ]
Tan, Daniel Shao-Weng [3 ]
Kim, Dong-Wan [4 ]
Orlov, Sergey [5 ]
Park, Keunchil [6 ]
Yu, Chong-Jen [7 ]
Mok, Tony [8 ]
Nishio, Makoto [9 ]
Scagliotti, Giorgio V. [10 ]
Spigel, David R. [11 ]
Sutradhar, Santosh [12 ]
Cesic, Dajana [12 ]
Shaw, Alice Tsang [13 ]
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Vall dHebron Univ, Barcelona, Spain
[3] Natl Canc Ctr, Singapore, Singapore
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] St Petersburg State Med Univ, Dept Thorac Oncol, St Petersburg, Russia
[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Innovat Canc Med Inst, Seoul, South Korea
[7] Natl Taiwan Univ, Taipei, Taiwan
[8] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[9] Japanese Fdn Canc Res, Tokyo, Japan
[10] Univ Turin, Turin, Italy
[11] Sarah Cannon Res Inst, Nashville, TN USA
[12] Novartis Pharmaceut, E Hanover, NJ USA
[13] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
NEURO-ONCOLOGY | 2016年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BMET-13
引用
收藏
页码：28 / 29
页数：7
相关论文
共 30 条
  • [1] Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK plus ) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and-3.
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Kim, Dong-Wan
    Mehra, Ranee
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Mok, Tony
    Nishio, Makoto
    Scagliotti, Giorgio V.
    Spigel, David R.
    Sutradhar, Santosh
    Cesic, Dajana
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naive Patients with ALK plus NSCLC and Brain Metastases: Results of ASCEND 1 and 3
    Shaw, Alice T.
    Spigel, David R.
    Tan, Daniel S. -W.
    Kim, Dong-Wan
    Mehra, Ranee
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Mok, Tony
    Nishio, Makoto
    Scagliotti, Giorgio
    Sutradhar, Santosh
    Cesic, Dajana
    Felip, Enriqueta
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S256 - S256
  • [3] Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials
    Felip, E.
    Crino, L.
    Kim, D. -W.
    Spigel, D. R.
    Nishio, M.
    Mok, T.
    Scagliotti, G.
    Cesic, D.
    Sutradhar, S.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S118 - S119
  • [4] Overall survival results of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC (ASCEND-3)
    Felip, E.
    Nishio, M.
    Orlov, S.
    Park, K.
    Yu, C-J.
    Tsai, C-M.
    Cobo, M.
    McKeage, M.
    Su, W-C.
    Mok, T. S. K.
    Scagliotti, G. V.
    Spigel, D.
    Passos, V. Q.
    Chen, Z.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2018, 29 : 745 - 745
  • [5] Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3
    Park, K.
    Tan, D.
    Ahn, M. -J.
    Yu, C. -J.
    Tsai, C. -M.
    Hida, T.
    Nishio, M.
    Branle, F.
    Emeremni, C.
    Mok, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 126 - 127
  • [6] Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
    Thomas, M.
    Schuler, M.
    Potzner, M.
    Szczudlo, T.
    Sutradhar, S.
    Yovine, A.
    Wolf, J.
    Oncology Research and Treatment, 2015, 38 : 270 - 270
  • [7] CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL
    Shaw, Alice
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Geraldes, Margarida
    Sen, Paramita
    Boral, Anthony J.
    Yovine, Alejandro
    Kim, Dong-Wan
    NEURO-ONCOLOGY, 2014, 16
  • [8] Phase 2 study of ceritinib in ALKi-naive patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
    Felip, E.
    Orlov, S.
    Park, K.
    Yu, C-J.
    Tsai, C-M.
    Nishio, M.
    Dols, M. C.
    McKeage, M.
    Su, W-C.
    Mok, T. S. K.
    Scagliotti, G.
    Spigel, D. R.
    Passos, V. Q.
    Chen, V.
    Munarini, F.
    Shaw, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] PROs with Ceritinib in ALKi-Naive ALK plus NSCLC Patients with and without Brain Metastases
    Park, Keunchil
    Felip, Enriqueta
    Orlov, Sergey
    Yu, Chong-Jen
    Tsai, Chun-Ming
    Nishio, Makoto
    Dols, Manuel Cobo
    Mckeage, Mark
    Su, Wu-Chou
    Mok, Tony
    Scagliotti, Giorgio V. V.
    Spigel, David R.
    Zhang, Jie
    Branle, Fabrice
    Emeremni, Chetachi
    Sutradhar, Santosh
    Quadrigli, Massimiliano
    Shaw, Alice
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S379 - S380
  • [10] Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
    Nishio, Makoto
    Felip, Enriqueta
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Tsai, Chun-Ming
    Cobo, Manuel
    McKeage, Mark
    Su, Wu-Chou
    Mok, Tony
    Scagliotti, Giorgio V.
    Spigel, David R.
    Viraswami-Appanna, Kalyanee
    Chen, Zhe
    Passos, Vanessa Q.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 609 - 617
123